Share on LinkedInShare on LinkedIn

ARTICLE · 18 AUGUST 2020

Bendeka® Patents Held To Be Valid – A Validity Analysis

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Cephalon sued ANDA filers for infringement of claims related to Bendeka®, a liquid formulation of bendamustine for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

United StatesIntellectual Property

Decision: Cephalon, Inc. v. Slayback Pharma LLC, No. 1:17-cv-01154 (D. Del. April 27, 2020).

Holding: Judge Connolly in the District of Delaware decided that all of Cephalon's asserted claims are valid and infringed.

Patents: 9,265,831; 9,572,797; 9,144,568; 9,597,399; 9,572,887

Background: Cephalon sued ANDA filers for infringement of claims related to Bendeka®, a liquid formulation of bendamustine for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Defendants unsuccessfully argued that the asserted formulation claims were invalid for obviousness, indefiniteness, lack of enablement and lack of written description. Defendants further unsuccessfully argued that the administration claims were invalid for obviousness.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from